Tozorakimab Phase III Results Could Broaden Biologic Treatment for COPD Patients

New Phase III results for AstraZeneca’s investigational COPD treatment tozorakimab could pave the way for biologic therapy to be offered to a broader group of patients, including people with low eosinophil counts.

Data from the OBERON and TITANIA trials suggest the interleukin-33 (IL-33) inhibitor can reduce exacerbations across a wider COPD population than many existing biologic treatments, according to healthcare intelligence and analytics company GlobalData.

AstraZeneca presented the full findings at the 2026 European Respiratory Society (ERS) Congress in Barcelona, with the results also published simultaneously in the New England Journal of Medicine.

Results Challenge Existing Approach to COPD Biologics

Biologic treatment for chronic obstructive pulmonary disease has largely focused on patients showing evidence of type 2 inflammation, often identified through elevated blood eosinophil counts.

However, the results for tozorakimab indicate that benefits may extend to patients with lower eosinophil levels.

Zaid Mahmood, Healthcare Analyst at GlobalData, said:

“With the results of TITANIA and OBERON, tozorakimab challenges the assumption that COPD biologics must be eosinophil-restricted to work, and the consistency across two replicate trials makes this one of the stronger COPD readouts documented in recent years.”

Tozorakimab reduced exacerbation rates among former smokers compared with placebo in both OBERON and TITANIA.

Of particular interest was the subgroup analysis based on blood eosinophil count (BEC). GlobalData said benefits were observed among patients with low eosinophil levels – a group in which COPD biologics have historically produced more limited results – while efficacy increased progressively as eosinophil levels rose.

Safety findings from the trials also indicated that tozorakimab was generally well tolerated. Discontinuations associated with severe adverse events were uncommon and were reported at comparable levels across the two studies.

Mahmood added:

“This is the first time a COPD biologic has shown efficacy across the eosinophil spectrum, including below the 150 thresholds, regardless of smoking status, which makes it a key differentiator from the other approved biologics currently in the market.”

Regulatory Reviews Underway

The results come as tozorakimab moves closer to a potential regulatory decision.

The US Food and Drug Administration has accepted the treatment’s biologics licence application for priority review, with a Prescription Drug User Fee Act (PDUFA) decision expected during the first quarter of 2027. Regulatory reviews are also underway in the European Union and China.

If approved for a broad COPD population, tozorakimab could strengthen AstraZeneca’s position in a growing market for biologic treatments.

Existing options include Sanofi and Regeneron’s Dupixent (dupilumab), which targets patients with COPD associated with type 2 inflammation. Other treatments and investigational therapies are also competing for a role in the expanding market.

Tozorakimab’s Phase III findings could prove particularly significant because of its performance across different eosinophil levels.

The development landscape for IL-33 therapies has also shifted during 2026. Sanofi discontinued development of its IL-33 inhibitor itepekimab for COPD following mixed Phase III findings, while other candidates remain under investigation.

Sanofi is continuing development of lunsekimig, a bispecific nanobody which produced Phase IIb asthma results presented at the ERS Congress and is also being investigated in a Phase IIb/III COPD trial.

COPD Market Forecast to Exceed $30bn

GlobalData believes the potential to treat patients irrespective of their eosinophil status could give tozorakimab an important point of differentiation if regulators approve the therapy.

Mahmood concluded:

“By demonstrating benefit across the eosinophil spectrum, tozorakimab is well positioned to become the first biologic approved for a broad COPD population rather than the narrower severe segment served by existing therapies. GlobalData forecasts the COPD market to grow to over $30 billion across the 7MM by 2034, with Dupixent, Nucala, and tozorakimab as the leading drugs.”

The findings could therefore represent an important development in the treatment of COPD, particularly for patients who have previously fallen outside the populations targeted by biologic medicines.